⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CELZ News
Creative Medical Technology Holdings, Inc. Common Stock
Form 8-K
sec.gov
CELZ
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
globenewswire.com
CELZ
Form 8-K
sec.gov
CELZ
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
globenewswire.com
CELZ
Form 8-K
sec.gov
CELZ
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
globenewswire.com
CELZ
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
globenewswire.com
CELZ
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
globenewswire.com
CELZ
Form 8-K
sec.gov
CELZ
Creative Medical Technology Holdings Issues Mid-Year Update
globenewswire.com
CELZ